Faron Pharmaceuticals Feed

	Est. tid*
2025-08-27	-	Kvartalsrapport 2025-Q2
2025-03-24	-	X-dag ordinarie utdelning FARON 0.00 EUR
2025-03-21	-	Årsstämma
2025-02-27	-	Bokslutskommuniké 2024
2024-08-28	-	Kvartalsrapport 2024-Q2
2024-03-25	-	X-dag ordinarie utdelning FARON 0.00 EUR
2024-03-22	-	Årsstämma
2024-03-14	-	Bokslutskommuniké 2023
2023-08-29	-	Kvartalsrapport 2023-Q2
2023-03-27	-	X-dag ordinarie utdelning FARON 0.00 EUR
2023-03-24	-	Årsstämma
2023-03-03	-	Bokslutskommuniké 2022
2022-08-25	-	Kvartalsrapport 2022-Q2
2022-07-07	-	Extra Bolagsstämma 2022
2022-04-25	-	X-dag ordinarie utdelning FARON 0.00 EUR
2022-04-22	-	Årsstämma
2022-03-25	-	Bokslutskommuniké 2021
2021-08-26	-	Kvartalsrapport 2021-Q2
2021-04-26	-	X-dag ordinarie utdelning FARON 0.00 EUR
2021-04-23	-	Årsstämma
2021-03-25	-	Bokslutskommuniké 2020
2020-05-14	-	X-dag ordinarie utdelning FARON 0.00 EUR
2020-05-13	-	Årsstämma
2020-03-20	-	Bokslutskommuniké 2019

Land	Finland
Lista	First North Finland
Sektor	Hälsovård
Industri	Bioteknik

2025-08-27 08:00:00 FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 2025 2,44 EUR | -6,33% | 2,27 MEUR

2025-08-19 08:00:00 Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results 2,65 EUR | +6,41% | 1,35 MEUR

2025-08-18 08:00:00 Inside Information: Faron to advance bexmarilimab into a registrational Phase 2/3 study in treatment-naïve (frontline) HR-MDS after positive meeting with the FDA 2,16 MEUR

2025-08-08 16:00:00 Faron Pharmaceuticals Ltd: Holding(s) in Company 2,44 EUR | +1,24% | 0,82 MEUR

2025-08-08 09:30:00 Faron announces extension to its key patent family around bexmarilimab and targeting Clever-1 in cancers with a new US patent granted 2,44 EUR | +1,24% | 0,82 MEUR

2025-08-07 08:00:00 Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds 2,41 EUR | -6,77% | 1,92 MEUR

2025-08-06 08:00:00 Inside Information: Faron to present updated BEXMAB data in frontline HR-MDS to FDA; complete remission rate substantially increased to 43% 2,58 EUR | +14,38% | 3,98 MEUR

2025-07-30 08:30:00 FARON ANNOUNCES ACCEPTANCE OF BEXMARILIMAB DATA FOR ORAL PRESENTATION AT ESMO 2025 2,19 EUR | -2,66% | 0,90 MEUR

2025-07-09 08:00:00 Faron announces acceptance of two studies involving bexmarilimab, one of them as an oral presentation, at the 19th International Congress of Immunology (IUIS) 2025 2,50 EUR | +0,60% | 0,56 MEUR

2025-07-02 12:00:00 Faron Pharmaceuticals Ltd: Director Dealing 2,58 EUR | +6,40% | 0,67 MEUR

2025-06-30 13:00:00 Faron Pharmaceuticals Ltd: Director/PCA Dealing 2,44 EUR | +7,00% | 1,05 MEUR

2025-06-30 08:00:00 Faron-supported research in Theranostics identifies secreted Clever-1 (sClever-1) as an independent driver of immune evasion in cancer, deepening the understanding of bexmarilimab’s mode of action 2,44 EUR | +7,00% | 1,05 MEUR

2025-06-12 08:00:00 Faron Pharmaceuticals presents updated Phase II data from BEXMAB Study at EHA 2025 2,73 EUR | +0,18% | 0,37 MEUR

2025-06-05 17:00:00 Faron Pharmaceuticals Ltd: Director/PCA Dealing and Donation of Shares to Foundation 2,55 EUR | +1,19% | 0,97 MEUR

2025-06-03 13:00:00 Faron Pharmaceuticals Ltd: Registration of New Shares 2,70 EUR | -10,60% | 2,97 MEUR

2025-06-03 08:00:00 Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds 2,70 EUR | -10,60% | 2,97 MEUR

2025-06-02 08:00:00 Faron Pharmaceuticals presents Phase II data from BEXMAB Study at ASCO 2025 3,02 EUR | -3,05% | 2,62 MEUR

2025-05-30 08:00:00 Faron announces publication of full Phase I BEXMAB study data in Lancet Haematology 3,12 EUR | +6,86% | 3,57 MEUR

2025-05-27 18:00:00 Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company 2,92 EUR | -4,43% | 1,45 MEUR

2025-05-27 08:00:00 Faron’s Bexmarilimab demonstrates immune-activating and drug-sensitizing potential in myeloid malignancies 3,05 EUR | +5,90% | 1,28 MEUR

2025-05-23 08:00:00 Faron announces new data that highlight patient populations with cancer that are most likely to benefit from first-in-class immunotherapy bexmarilimab 2,88 EUR | -3,52% | 1,99 MEUR

2025-05-21 08:00:00 Faron Appoints Ralph Hughes as Chief Business Officer (CBO) 2,87 EUR | +4,36% | 1,39 MEUR

2025-05-15 08:00:00 Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 Congress 2,59 EUR | -1,89% | 0,60 MEUR

2025-05-14 15:00:00 Faron Pharmaceuticals Ltd: Grant of Options 2,64 EUR | -1,49% | 0,40 MEUR

2025-05-12 08:00:00 Faron Pharmaceuticals presents promising Phase 1/2 data from BEXMAB Study at MDS 2025 plenary session 2,65 EUR | -4,68% | 1,16 MEUR

2025-04-24 08:00:00 Faron announces acceptance of bexmarilimab Phase II data for oral presentation at ASCO 2025 2,42 EUR | -1,02% | 0,39 MEUR

2025-04-17 14:15:00 Holding in Company 2,44 EUR | +6,09% | 3,51 MEUR

2025-04-15 08:10:00 Sisäpiiritieto: Faron julkistaa positiivisia II vaiheen tuloksia hoitoresistentin korkeariskin myelodysplastisen syndrooman hoidossa 2,70 EUR | -7,69% | 4,82 MEUR

2025-04-15 08:00:00 Inside Information: Faron Announces Positive Phase II results in higher-risk myelodysplastic syndrome 2,70 EUR | -7,69% | 4,82 MEUR

2025-04-03 08:00:00 Inside Information: Faron enters into an up to EUR 35 million convertible bond arrangement and issues first tranche of bonds with a principal amount of EUR 15 million 2,50 EUR | -8,61% | 2,61 MEUR

2025-03-27 08:00:00 Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at 2025 Annual MDS Foundation Congress 2,58 EUR | +5,74% | 0,91 MEUR

2025-03-21 14:15:00 Board Changes 2,30 EUR | -5,93% | 0,61 MEUR

2025-03-21 12:45:00 Results of the Annual General Meeting, Change of Directors, Decision of the Board meeting after the AGM 2,30 EUR | -5,93% | 0,61 MEUR

2025-03-20 08:00:00 Shareholders’ Nomination Board updates its recommendation on the number of Board members to be elected and the persons proposed to be elected 2,44 EUR | +6,54% | 0,85 MEUR

2025-03-03 13:00:00 Inside Information: FDA Grants Orphan Drug Designation for Bexmarilimab in MDS 2,10 EUR | +4,48% | 1,09 MEUR

2025-02-28 13:00:00 NOTICE OF FARON PHARMACEUTICALS LTD’S ANNUAL GENERAL MEETING 2,01 EUR | -0,99% | 0,21 MEUR

2025-02-27 08:30:00 Inside Information: Faron Receives Positive EMA Opinion on Orphan Drug Designation for Bexmarilimab for the treatment of myelodysplastic syndrome (MDS) 2,03 EUR | +1,60% | 0,52 MEUR

2025-02-27 08:15:00 Faron Pharmaceuticals Ltd’s Annual Report 2024 published 2,03 EUR | +1,60% | 0,52 MEUR

2025-02-27 08:00:00 Faron’s Financial Statement Release 1 January to 31 December 2024 2,03 EUR | +1,60% | 0,52 MEUR

2025-02-19 11:00:00 Faron Pharmaceuticals will publish its Financial Statement Release 2024 and Annual Report 2024 on Thursday 27 February 2025 2,02 EUR | -3,81% | 0,24 MEUR

2025-02-14 13:00:00 Holding(s) in Company 2,04 EUR | -2,40% | 0,28 MEUR

2025-02-11 08:30:00 Change of Broker 1,91 EUR | -1,44% | 0,83 MEUR

2025-02-06 16:00:00 Holding(s) in Company 2,11 EUR | +10,01% | 15,9 MEUR

2025-02-06 08:00:00 Results of the Significantly Oversubscribed Placing 2,11 EUR | +10,01% | 15,9 MEUR

2025-02-05 17:30:00 Proposed Issue and Placing 2,11 EUR | +10,01% | 15,9 MEUR

2025-01-31 08:00:00 Final Patient Identified for the BEXMAB Study 2,04 EUR | -3,33% | 0,73 MEUR

2024-06-05 09:00:00 Proposed REX Retail Offer 1,28 EUR | -2,74% | 1,09 MEUR

2024-06-04 08:00:00 Faron commences a share offering 1,31 EUR | -44,20% | 2,52 MEUR

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Faron Pharmaceuticals

Prenumeration

Kalender

Beskrivning

Faron Pharmaceuticals

Prenumeration

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden